STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

News

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

Rhea-AI Summary
Tonix Pharmaceuticals announces poster presentation at CICON23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
News

Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024

Rhea-AI Summary
Tonix Pharmaceuticals commits to meeting potential increased demand for Tosymra nasal spray 10 mg after GlaxoSmithKline discontinues Imitrex nasal spray 5 mg and 20 mg products in January 2024. Tonix is prepared to alleviate potential shortages in sumatriptan, a widely used treatment for acute migraine. Intranasal sumatriptan is recommended for patients with severe nausea or vomiting during attacks. Tosymra is differentiated from generic equivalents due to its proprietary absorption enhancer technology, providing quick pain relief in as little as 10 minutes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Rhea-AI Summary
Tonix Pharmaceuticals announces topline results from Phase 2 study of TNX-102 SL for fibromyalgia-type Long COVID
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
clinical trial covid-19
News

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

Rhea-AI Summary
Tonix Pharmaceuticals to commence Phase 1/2 clinical trial for TNX-801 vaccine after receiving FDA feedback
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
-
News

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced that its Chief Medical Officer will present at the August 2023 Virtual Investor Summit. Tonix is a biopharmaceutical company focused on developing therapeutics for various diseases. Its lead candidate, TNX-102 SL, is in mid-Phase 3 development for fibromyalgia. Tonix also has candidates for major depressive disorder, rare diseases, immunology, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Rhea-AI Summary
Tonix Pharmaceuticals has initiated a Phase 1 study of TNX-1500, a biologic candidate for the prevention of kidney transplant rejection and other transplant and autoimmune disorders. The study aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of TNX-1500 in healthy volunteers. TNX-1500 has shown promise in animal studies, preventing organ rejection and preserving graft function. The initiation of this study supports dosing in a planned Phase 2 trial in kidney transplant recipients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
clinical trial
News

Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced financial results for Q2 2023 and provided an overview of recent operational highlights. The company completed enrollment in four clinical trials for CNS indications and expects to release topline results for fibromyalgia, fibromyalgia-type Long COVID, chronic migraine, and depression before the end of 2023. Tonix also completed the acquisition of two acute migraine products, Zembrace SymTouch and Tosymra, which generated approximately $30 million in sales for the past year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
earnings
-
News

Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
covid-19
-
News

Tonix Pharmaceuticals Announces Closing of $7 Million Public Offering

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
offering
News

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
clinical trial

FAQ

What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?

The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.19 as of November 22, 2024.

What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?

The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 38.2M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.

Stock TNXP logo
Tonix Pharmaceuticals Holding Corp.

Nasdaq:TNXP

TNXP Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends

TNXP Stock Data

38.16M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHATHAM